Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma

Article Oncology

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok et al.

Summary: The 6.5-year results of the CheckMate 067 trial demonstrate durable clinical benefits with nivolumab plus ipilimumab or nivolumab monotherapy compared to ipilimumab alone in patients with advanced melanoma.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Circulating Tumour DNA in Melanoma-Clinic Ready?

Ann Tivey et al.

Summary: Liquid biopsies, such as ctDNA, have potential to provide real-time information about disease status in patients with melanoma. Rigorous testing within clinical trials is needed to assess how ctDNA can be optimally used to benefit patients in the clinic.

CURRENT ONCOLOGY REPORTS (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Diagnostic Test Accuracy of F-18-FDG PET or PET/CT in Merkel Cell Carcinoma

Sung Ryul Shim et al.

Summary: This study evaluated the diagnostic accuracies of F-18-FDG PET or PET/CT for Merkel cell carcinoma (MCC) through a systematic review and meta-analysis. The results showed that F-18-FDG PET/CT had excellent performance in diagnosing MCC and could be useful for exclusion and confirmation of the disease. Further large multicenter studies are needed to validate its diagnostic accuracy.

CLINICAL NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Oncology

Case report: Rea world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios

Karam Khaddour et al.

Summary: Circulating-tumor DNA (ctDNA) is an important biomarker for monitoring cancer patients. Different ctDNA testing platforms have shown promising results in early disease detection, treatment response monitoring, and prognosis in metastatic melanoma. However, challenges exist in reducing shedding of ctDNA, sensitivity differences among assays, and distinguishing tumor-specific mutations. A personalized, tumor-informed ctDNA assay could provide more accurate monitoring of metastatic melanoma. This case series describes the use of such an assay to monitor four patients and highlights the potential benefits and limitations in clinical decision-making.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

Sungjune Kim et al.

Summary: This study evaluated the efficacy of combined nivolumab and ipilimumab in treating Merkel cell carcinoma. The results showed clinical benefits in both first-line treatment and in patients who had previously received anti-PD-1 and PD-L1 therapy. However, the addition of SBRT did not improve the treatment outcomes.

LANCET (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Zengfu Zhang et al.

Summary: Radiotherapy can not only control local tumors, but also have a systemic effect on remote and non-irradiated tumors. The combination of radiotherapy and immunotherapy has a strong rationale and can be used as a radical and systemic treatment option.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

添加到收藏夹

Article Surgery

Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases A Prospective, Open-label, Randomized, Controlled Trial

Karim Boudjema et al.

Summary: This study compared simultaneous resection and delayed resection of synchronous colorectal cancer liver metastases, finding no significant difference in the rate of major complications between the two groups. However, delayed resection tended to impair overall survival.

ANNALS OF SURGERY (2021)

添加到收藏夹

Article Oncology

Melanoma: Cutaneous, Version 2.2021 Featured Updates to the NCCN Guidelines

Susan M. Swetter et al.

Summary: In recent years, the NCCN Guidelines for Melanoma: Cutaneous have expanded to include pathways for microscopic satellitosis, molecular testing, systemic therapy considerations, and brain metastases management. The latest update in v1.2021 includes additional modifications to pathology, surgical margins, lymph node biopsy, lymph node dissection, and radiation therapy recommendations.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Review Oncology